ClubsMakklerPROMarketsEconomic CalendarEarnings CalendarNewsMakklerAIFamous Investors
ENTRDE
Log InGet Started Free
OverviewStocksCryptoCurrenciesCommoditiesETFsOptionsEconomic CalendarEarnings CalendarGuru PortfoliosMy watchlist

Makkler App

Faster and clearer

Install
Overview/Stocks/AZR

Azora Therapeutics, Inc. AZR

NASDAQHealth TechnologyUnited States
$4.00+0.29 (+7.82%)

Market closed· Nov 6, 2026, 9:00 PM UTC· USD · Data may be delayed

Day's range
3.764.00
52-week range
1.318.75

Financial health

– / 5

Analyst view · 5 firms

Buy5 buy · 0 hold · 0 sell

Avg. target $10.75 (+168.8%)

OverviewFinancialsAnalysisEarningsTechnicalsHistorical dataNews

Prices may be delayed and are for informational purposes only - not investment advice.

Trend
MixedAgainst the 50- and 200-day averages
Period change
-51.52%Last 12 months · total return incl. dividends
Range position
38%$1.36 – $8.25
Volatility
112.0%Annualized

Price and moving averages

Last year · daily close

Price20D50D200D

Moving averages

AverageValuePrice vs. averageDifference
20D avg.$3.85above+3.8%
50D avg.$4.50below-11.2%
200D avg.$3.18above+25.7%
Avg. volume (1Y)160.04K

All indicators are computed from the last year of daily closes. Returns and volatility use the dividend-adjusted series; averages and highs/lows use the traded price. Not investment advice.

Overview
Stocks
Crypto
Currencies
Commodities
ETFs
Options
Economic Calendar
Earnings Calendar
Guru Portfolios
My watchlist
See with MakklerPRO
Details
Clubs
MakklerPRO
Markets
Economic Calendar
Earnings Calendar
News
MakklerAI
Famous Investors
Log In
Get Started Free

The portfolio-sharing platform connecting finance analysts with an audience that wants to learn.

Theme
Platform
ClubsMarketsMarkets NewsMakklerPROMakkler TokenHow It WorksBecome an Analyst
Compare
Makkler vs. eToroMakkler vs. SkoolMakkler vs. YouTube
Company
About UsContact
Legal
Terms of ServicePrivacy PolicyData Protection NoticeRisk DisclosurePayment Policy

© 2026 Makkler, LLC. All rights reserved. Content on this platform does not constitute investment advice.

ENTRDE